Press Releases

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

November 5, 2019

Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference

October 31, 2019

Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance

October 28, 2019

Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting

October 17, 2019

Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call

September 18, 2019

Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China

August 28, 2019

Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

August 13, 2019

Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment

August 13, 2019

Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)

August 8, 2019

Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering

August 6, 2019

Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes

July 30, 2019

Ironwood Pharmaceuticals Reports Second Quarter 2019 Results

July 18, 2019

Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call

June 18, 2019

Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

June 13, 2019

Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston

June 3, 2019

Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D

May 9, 2019

Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019

May 7, 2019

Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference

May 2, 2019

Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance

April 18, 2019

Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call

April 16, 2019

Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020

April 1, 2019

Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company

March 14, 2019

Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

March 7, 2019

Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference

March 4, 2019

Ironwood Pharmaceuticals to Present at Cowen Health Care Conference

February 26, 2019

Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering

February 21, 2019

Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

February 13, 2019

Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update

January 28, 2019

Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2018 Investor Update Call

January 28, 2019

Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation

January 15, 2019

Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C

January 6, 2019

Ironwood Pharmaceuticals Appoints Michael Shetzline, M.D., Ph.D. as Chief Medical Officer

January 4, 2019

Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation

January 2, 2019

Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

January 2, 2019

Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation